학술논문

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
Document Type
Article
Source
In Annals of Oncology May 2024 35(5):429-436
Subject
Breast tumors
Language
ISSN
0923-7534